Pacific Biosciences Of California (PACB) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Pacific Biosciences Of California (PACB) over the last 14 years, with Q4 2024 value amounting to $81.9 million.
- Pacific Biosciences Of California's Accumulated Depreciation & Amortization rose 956.49% to $81.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $81.9 million, marking a year-over-year increase of 956.49%. This contributed to the annual value of $81.9 million for FY2024, which is 956.49% up from last year.
- According to the latest figures from Q4 2024, Pacific Biosciences Of California's Accumulated Depreciation & Amortization is $81.9 million, which was up 956.49% from $74.8 million recorded in Q4 2023.
- Pacific Biosciences Of California's 5-year Accumulated Depreciation & Amortization high stood at $81.9 million for Q4 2024, and its period low was $49.9 million during Q4 2020.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $65.0 million (2022), whereas its average is $65.6 million.
- As far as peak fluctuations go, Pacific Biosciences Of California's Accumulated Depreciation & Amortization soared by 1546.03% in 2022, and later skyrocketed by 956.49% in 2024.
- Quarter analysis of 5 years shows Pacific Biosciences Of California's Accumulated Depreciation & Amortization stood at $49.9 million in 2020, then grew by 12.82% to $56.3 million in 2021, then increased by 15.46% to $65.0 million in 2022, then rose by 15.09% to $74.8 million in 2023, then grew by 9.56% to $81.9 million in 2024.
- Its last three reported values are $81.9 million in Q4 2024, $74.8 million for Q4 2023, and $65.0 million during Q4 2022.